ATE283047T1 - Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose - Google Patents

Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose

Info

Publication number
ATE283047T1
ATE283047T1 AT98936715T AT98936715T ATE283047T1 AT E283047 T1 ATE283047 T1 AT E283047T1 AT 98936715 T AT98936715 T AT 98936715T AT 98936715 T AT98936715 T AT 98936715T AT E283047 T1 ATE283047 T1 AT E283047T1
Authority
AT
Austria
Prior art keywords
ibudilast
multiple sclerosis
treatment
production
medicinal product
Prior art date
Application number
AT98936715T
Other languages
English (en)
Inventor
Saburo Sakoda
Original Assignee
Kyorin Seiyaku Kk
Saburo Sakoda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk, Saburo Sakoda filed Critical Kyorin Seiyaku Kk
Application granted granted Critical
Publication of ATE283047T1 publication Critical patent/ATE283047T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Forklifts And Lifting Vehicles (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
AT98936715T 1998-08-10 1998-08-10 Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose ATE283047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1998/003548 WO2000009127A1 (fr) 1998-08-10 1998-08-10 Traitements contre la sclerose en plaques

Publications (1)

Publication Number Publication Date
ATE283047T1 true ATE283047T1 (de) 2004-12-15

Family

ID=14208769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98936715T ATE283047T1 (de) 1998-08-10 1998-08-10 Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose

Country Status (11)

Country Link
US (1) US6395747B1 (de)
EP (1) EP1106178B1 (de)
JP (1) JP4828003B2 (de)
AT (1) ATE283047T1 (de)
AU (1) AU8562198A (de)
CA (1) CA2339934C (de)
DE (1) DE69827853T2 (de)
DK (1) DK1106178T3 (de)
ES (1) ES2231998T3 (de)
PT (1) PT1106178E (de)
WO (1) WO2000009127A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1570847B1 (de) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a-hemmer zur behandlung der parkinson-krankheit, der huntington-krankheit und der schizophrenie
CA2546347A1 (en) * 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
US20060093578A1 (en) * 2004-11-04 2006-05-04 Kyorin Pharmaceutical Co., Ltd. Method and composition for treating multiple sclerosis
JP4954085B2 (ja) * 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
KR100780479B1 (ko) 2006-05-08 2007-11-28 윈셋파마 주식회사 이부딜라스트 함유 경구용 제제 및 이의 제조방법
CA2653345A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
PT2131841E (pt) * 2007-01-30 2012-09-24 Univ Colorado Regents Métodos para tratar a dor aguda e sub-crónica
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
AU2008275148A1 (en) * 2007-07-11 2009-01-15 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
JP2020504721A (ja) 2016-12-22 2020-02-13 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． イブジラストを使用した多形膠芽腫の治療方法
ES2959799T3 (es) * 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
CA3090884A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3135420A1 (en) * 2018-04-05 2019-10-10 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
JP2022504435A (ja) 2018-10-09 2022-01-13 メディシノバ・インコーポレイテッド イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法
EP3866788B1 (de) 2018-10-19 2023-12-13 MediciNova, Inc. Behandlung von mit multipler sklerose verbundener makularer verletzung mit ibudilast
WO2020251748A1 (en) * 2019-06-11 2020-12-17 Yale University Novel treatment for wolfram syndrome
WO2021061554A1 (en) 2019-09-23 2021-04-01 Medicinova, Inc. Ibudilast oral formulations and methods of using same
EP4132521A1 (de) 2020-04-06 2023-02-15 MediciNova, Inc. Verfahren zur reduzierung des plasmaspiegels des makrophagen-migrationshemmenden faktors bei patienten mit ibudilast
WO2022164948A1 (en) 2021-01-29 2022-08-04 Medicinova, Inc. Methods of treating chemical gas exposure
EP4376838A1 (de) 2021-07-26 2024-06-05 MediciNova, Inc. Ibudilast zur prävention von augenkrebsmetastasen
US20230090534A1 (en) 2021-09-21 2023-03-23 Medicinova, Inc. Methods of treating glioblastoma multiforme using combination therapy
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
US20230285367A1 (en) 2022-02-01 2023-09-14 Medicinova, Inc. Methods of treating post-covid condition(s)
WO2024015415A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
MX9701600A (es) * 1994-08-29 1997-05-31 Yamanouchi Pharma Co Ltd Derivados de naftiridina novedosos y composicion medicinal de los mismos.

Also Published As

Publication number Publication date
WO2000009127A1 (fr) 2000-02-24
PT1106178E (pt) 2005-02-28
DE69827853T2 (de) 2005-12-08
EP1106178A4 (de) 2001-11-21
JP4828003B2 (ja) 2011-11-30
ES2231998T3 (es) 2005-05-16
AU8562198A (en) 2000-03-06
CA2339934A1 (en) 2000-02-24
DK1106178T3 (da) 2005-02-28
EP1106178B1 (de) 2004-11-24
CA2339934C (en) 2008-06-03
EP1106178A1 (de) 2001-06-13
DE69827853D1 (de) 2004-12-30
US6395747B1 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
ATE283047T1 (de) Verwendung von ibudilast zur herstellung eines arzneimittels zur behandlung multiple sklerose
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NO870241D0 (no) Hypoglykemiske tiazolidindioner.
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
HUP0203325A2 (hu) Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE3879873D1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE3873578D1 (de) Verwendung von tetrahydrobenz(c,d)indol-6-carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
ATE123944T1 (de) Verwendung von trifluormethylphenyl- tetrahydropyridinen zur herstellung von arzneimitteln zur behandlung anxio-depressiver erkrankungen.
DE3785740D1 (de) Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie.
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
DE3878111D1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
ATE157871T1 (de) Arzneimittel zur therapeutischen und prophylaktischen behandlung von krankheiten, die durch hyperplasie der glatten muskelzellen bedingt sind
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
TNSN97143A1 (fr) Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
ATE110568T1 (de) Pharmazeutisches präparat zur behandlung des katarakts.
DE69619868D1 (de) Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso
DE69424415D1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
FR2447368A1 (fr) Derives de la phenylethylamine, leur preparation et medicament contenant ces substances

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1106178

Country of ref document: EP